Résumé
En lien avec la fréquence du tabagisme et du syndrome métabolique, les patients souffrant de schizophrénie ont une prévalence élevée de pathologies organiques et un risque de mortalité prématurée deux à trois fois supérieur à celui constaté en population générale. Concernant le cancer, la prévalence globale serait au moins égale à celle retrouvée en population générale, mais la mortalité supérieure, principalement pour le cancer du sein chez la femme. Cet article propose une synthèse des principaux résultats épidémiologiques, ainsi que des facteurs de risque et de protection impliqués.
Abstract
Partly due to the frequency of smoking and metabolic syndrome, patients with schizophrenia have a higher prevalence of somatic diseases and a rate of premature death 2–3 times higher than in the general population. The global prevalence of cancer is at least as high in patients with schizophrenia in comparison to the general population, and higher mortality, especially for breast cancer in women. This article is a review of epidemiologic data on the topic, and of the risk and protection factors involved in the comorbidity between cancer and schizophrenia.
This is a preview of subscription content, log in via an institution to check access.
Références
Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361–71
Buda M, Tsuang MT, Fleming JA (1988) Causes of death in DSM-III schizophrenics and other psychotics (atypical group). A comparison with the general population. Arch Gen Psychiatry 45(3):283–5
Cohen M, Dembling B, Schorling J (2002) The association between schizophrenia and cancer: a population-based mortality study. Schizophr Res 57(2–3):139–46
Dalton SO, Johansen C, Poulsen AH, et al (2006) Cancer risk among users of neuroleptic medication: a population-based cohort study. Br J Cancer 95(7):934–9
De Hert M, Van Winkel R, Van Eyck D, et al (2006) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2:14
Direction de la recherche, des études, de l’évaluation et des statistiques (DREES) (2005) Données sur la situation sanitaire et sociale en France en 2005. Annexe 1 au projet de loi de financement de la Sécurité sociale pour 2006
Fors BM, Isacson D, Bingefors K, et al (2007) Mortality among persons with schizophrenia in Sweden: an epidemiological study. Nord J Psychiatry 61(4):252–9
Huber JC, Schneeberger C, Tempfer CB (2002) Genetic modeling of the estrogen metabolism as a risk factor of hormone-dependent disorders. Maturitas 42(1):1–12
Kanakry CG, Li Z, Nakai Y, et al (2007) Neuregulin-1 regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/Akt-dependent pathway: potential implications for schizophrenia and cancer. PLoS One 2(12):e1369
Kilbourne AM, Cornelius JR, Han X, et al (2005) General-medical conditions in older patients with serious mental illness. Am J Geriatr Psychiatry 13(3):250–4
Kronfol Z, Remick DG (2000) Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157(5):683–94
Levav I, Lipshitz I, Novikov I, et al (2007) Cancer risk among parents and siblings of patients with schizophrenia. Br J Psychiatry 190:156–61
Levina W, Nolen B, Su Y, et al (2009) Biological significance of prolactin in gynaecologic cancers. Cancer Res 69(12):5226–33
Limosin F, Loze JY, Philippe A, et al (2007) Ten-year prospective study of the mortality by suicide in schizophrenic patients. Schizophr Res 94(1–3):23–8
McEvoy JP, Meyer JM, Goff DC, et al (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80(1):19–32
Mortensen PB, Juel K (1990) Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr Scand 81(4):372–7
Mortensen PB, Juel K (1993) Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 163:183–9
Nasrallah HA, Meyer JM, Goff DC, et al (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86(1–3):15–22
Ösby U, Correia N, Brandt L, et al (2000) Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 321(7259):483–4
Richet-Mastain L (2007) Bilan démographique 2006: un excédent naturel record. Insee Première no 1118
Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64(10):1123–31
Tran E, Rouillon F, Loze JY, et al (2009) Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer 115(15):3555–62
Waddington JL, Youssef HA, Kinsella A (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173:325–9
Yu Y, Wan Y, Huang C (2009) The biological functions of NK-kappaB1 (p50) and its potential as an anti-cancer target. Curr Cancer Drug Targets 9(4):566–71
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Limosin, F. Cancer et schizophrénie : données épidémiologiques et hypothèses étiopathogéniques. Psycho Oncologie 4, 7–11 (2010). https://doi.org/10.1007/s11839-010-0238-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11839-010-0238-6